Comparative analysis of Alzheimer’s disease Cerebrospinal fluid biomarkers measurement by multiplex SOMAscan platform and immunoassay-based approach

Manuscript Number: 

22-0399R1

Author(s): 
Miguel Aguilar, Randall J. Bateman, Jasmeer Chhatwal, Carlos Cruchaga, Anh Do, Anne M. Fagan, Martin R. Farlow, Duber Gomez-Fonseca, Jason Hassenstab, Rachel L. Henson, Elizabeth Herries, Hiroshi Mori, John C. Morris, Krista Moulder, Pau Pastor, Richard J. Perrin, Suzanne Schindler, Yun Ju Sung, Jigyasha Timsina, Jonathan Vöglein, Lihua Wang, Dan Western, Chengjie Xiong, Ignacio Álvarez

Disclosures

Miguel Aguilar

  • Nothing to Disclose

Ignacio Álvarez

  • Nothing to Disclose

Randall J. Bateman

  • Consulting Fees:
    Consulting Fees paid to R. Bateman from Amgen and Hoffman La-Roche. Is part of the Roche/Genentech Gantenerumab Advisory Committee. Receives income from C2N Diagnostics foe serving on the scientific Advisory Board.
    Lecture Fees:
    Received honoraria from the Korean Dementia Association for an International Conference Lecture. Received honoraria from the American Neurological Association for a Fall Conference Lecture.
    Patents/Royalties
    Equity ownership interest in C2N Diagnostics and receives royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. Washington University, with RJB as coinventor, has submitted the US nonprovisional patent application 16/610,428 “Plasma Based Methods for Determining A-Beta Amyloidosis.”
    Grants
    • Agency: 
      NIH NIA Grants
      Dates: 
      2016.07.15-2021.04.30
    • Agency: 
      National Institute of Aging
      Dates: 
      2016.07.15-2021.04.30
    • Agency: 
      Hoffman La-Roche/Genentech
      Dates: 
      2021.08.01-2024.12.28
    • Agency: 
      Eli Lilly & Co.
      Dates: 
      2016.02.01-2023.02.03
    • Agency: 
      Biogen
      Dates: 
      2016.02.01-2024.12.28
    • Agency: 
      AbbVie
      Dates: 
      2016.02.01-2024.12.28
    • Agency: 
      Bristol Myers Squibb
      Dates: 
      2021.08.01-2024.12.28
    • Agency: 
      Novartis
      Dates: 
      2016.02.01-2023.02.03

Jasmeer Chhatwal

  • Nothing to Disclose

Carlos Cruchaga

  • Grants
    • Agency: 
      GSK
      Dates: 
      from Jan 2022 to Jan 2025

Anh Do

  • Nothing to Disclose

Anne M. Fagan

  • Consulting Fees:
    Dr. Fagan is a member of the scientific advisory boards for Roche Diagnostics, Genentech and Diadem and also consults for DiamiR and Siemens Healthcare Diagnostics Inc. There are no conflicts.

Martin R. Farlow

  • Consulting Fees:
    Artery Therapeutics (ATI); Athira; Avanir; AZTherapies; Biogen MA; Cognition Therapeutics; Cyclo Therapeutics; Gemvax; Green Valley; Ionis; Lexeo; Longeveron; McClena; Merck; Nervive; Neurotrope Bioscience; Oligomerix; Otsuka Pharmaceutical; Pinteon; Proclara; Prothena; SToP-AD; Vaxinity

Duber Gomez-Fonseca

  • Nothing to Disclose

Jason Hassenstab

  • Consulting Fees:
    Paid consultant for Roche and Parabon Nanolabs.

Rachel L. Henson

  • Nothing to Disclose

Elizabeth Herries

  • Nothing to Disclose

Hiroshi Mori

  • Nothing to Disclose

John C. Morris

  • Consulting Fees:
    LEADS steering committee; CBR Int'l Advisory Board meeting

Krista Moulder

  • Nothing to Disclose

Pau Pastor

  • Lecture Fees:
    Neuraxpharm and Ipsen Pharma

Richard J. Perrin

  • Nothing to Disclose

Suzanne Schindler

  • Nothing to Disclose

Yun Ju Sung

  • Nothing to Disclose

Jigyasha Timsina

  • Nothing to Disclose

Jonathan Vöglein

  • Nothing to Disclose

Lihua Wang

  • Nothing to Disclose

Dan Western

  • Nothing to Disclose

Chengjie Xiong

  • Nothing to Disclose